These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24929624)

  • 1. Impact of sitagliptin on carotid intima-media thickness in patients with coronary artery disease and impaired glucose tolerance or mild diabetes mellitus.
    Ishikawa S; Shimano M; Watarai M; Koyasu M; Uchikawa T; Ishii H; Inden Y; Takemoto K; Murohara T
    Am J Cardiol; 2014 Aug; 114(3):384-8. PubMed ID: 24929624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: A one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease.
    Koyasu M; Ishii H; Watarai M; Takemoto K; Inden Y; Takeshita K; Amano T; Yoshikawa D; Matsubara T; Murohara T
    Clin Ther; 2010 Aug; 32(9):1610-7. PubMed ID: 20974318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial.
    Mita T; Katakami N; Shiraiwa T; Yoshii H; Onuma T; Kuribayashi N; Osonoi T; Kaneto H; Kosugi K; Umayahara Y; Yamamoto T; Matsumoto K; Yokoyama H; Tsugawa M; Gosho M; Shimomura I; Watada H;
    Diabetes Care; 2016 Mar; 39(3):455-64. PubMed ID: 26822324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
    McCormick LM; Kydd AC; Read PA; Ring LS; Bond SJ; Hoole SP; Dutka DP
    Circ Cardiovasc Imaging; 2014 Mar; 7(2):274-81. PubMed ID: 24503784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study.
    Hage C; Brismar K; Efendic S; Lundman P; Rydén L; Mellbin L
    J Intern Med; 2013 Apr; 273(4):410-21. PubMed ID: 23331339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors.
    Barbieri M; Rizzo MR; Marfella R; Boccardi V; Esposito A; Pansini A; Paolisso G
    Atherosclerosis; 2013 Apr; 227(2):349-54. PubMed ID: 23375680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats.
    Lim S; Choi SH; Shin H; Cho BJ; Park HS; Ahn BY; Kang SM; Yoon JW; Jang HC; Kim YB; Park KS
    PLoS One; 2012; 7(4):e35007. PubMed ID: 22493727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
    Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
    Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial.
    Oyama J; Murohara T; Kitakaze M; Ishizu T; Sato Y; Kitagawa K; Kamiya H; Ajioka M; Ishihara M; Dai K; Nanasato M; Sata M; Maemura K; Tomiyama H; Higashi Y; Kaku K; Yamada H; Matsuhisa M; Yamashita K; Bando YK; Kashihara N; Ueda S; Inoue T; Tanaka A; Node K;
    PLoS Med; 2016 Jun; 13(6):e1002051. PubMed ID: 27351380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cotreatment with the α-glucosidase inhibitor miglitol and DPP-4 inhibitor sitagliptin improves glycemic control and reduces the expressions of CVD risk factors in type 2 diabetic Japanese patients.
    Imai C; Saito M; Mochizuki K; Fuchigami M; Goda T; Osonoi T
    Metabolism; 2014 Jun; 63(6):746-53. PubMed ID: 24559582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
    Erol A
    Clin Ther; 2008 Apr; 30(4):785-6; author reply 786. PubMed ID: 18498926
    [No Abstract]   [Full Text] [Related]  

  • 15. Sitagliptin on carotid intima-media thickness in type 2 diabetes patients receiving primary or secondary prevention of cardiovascular disease: A subgroup analysis of the PROLOGUE study.
    Tanaka A; Yoshida H; Nanasato M; Oyama JI; Ishizu T; Ajioka M; Ishiki R; Saito M; Shibata Y; Kaku K; Maemura K; Higashi Y; Inoue T; Murohara T; Node K
    Int J Cardiol; 2018 Nov; 271():331-335. PubMed ID: 29803341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.
    Matsubara J; Sugiyama S; Akiyama E; Iwashita S; Kurokawa H; Ohba K; Maeda H; Fujisue K; Yamamoto E; Kaikita K; Hokimoto S; Jinnouchi H; Ogawa H
    Circ J; 2013; 77(5):1337-44. PubMed ID: 23386232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes: a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE).
    Katakami N; Mita T; Irie Y; Takahara M; Matsuoka TA; Gosho M; Watada H; Shimomura I;
    Cardiovasc Diabetol; 2018 Feb; 17(1):24. PubMed ID: 29402270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.
    Satoh-Asahara N; Sasaki Y; Wada H; Tochiya M; Iguchi A; Nakagawachi R; Odori S; Kono S; Hasegawa K; Shimatsu A
    Metabolism; 2013 Mar; 62(3):347-51. PubMed ID: 23062489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes.
    Li B; Luo YR; Tian F; Chen YD; Tian JW; Ding Y; Zhu M; Li JW; Zhang YQ; Shi WM
    Atherosclerosis; 2020 May; 300():10-18. PubMed ID: 32247073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.
    van Genugten RE; van Raalte DH; Muskiet MH; Heymans MW; Pouwels PJ; Ouwens DM; Mari A; Diamant M
    Eur J Endocrinol; 2014 Mar; 170(3):429-39. PubMed ID: 24297090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.